This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Jun;2(6):923-8.

doi: 10.4155/fmc.10.181.

The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development

Xiang-Qing Yu¹, Alan G E Wilson

Affiliations

PMID: 21426110
DOI: 10.4155/fmc.10.181

The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development

Xiang-Qing Yu et al. Future Med Chem. 2010 Jun.

. 2010 Jun;2(6):923-8.

doi: 10.4155/fmc.10.181.

Authors

Xiang-Qing Yu¹, Alan G E Wilson

Affiliation

¹ Drug Metabolism, Pharmacokinetics, Toxicology and Pathology, Lexicon Pharmaceuticals, Inc., The Woodlands, TX 77381, USA.

PMID: 21426110
DOI: 10.4155/fmc.10.181

No abstract available

PubMed Disclaimer

Similar articles

Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
Peters SA, Ungell AL, Dolgos H. Peters SA, et al. Curr Opin Drug Discov Devel. 2009 Jul;12(4):509-18. Curr Opin Drug Discov Devel. 2009. PMID: 19562647 Review.
Biomarkers and biomeasures: key enablers for pharmacokinetic-pharmacodynamic modeling in drug discovery and development.
Agoram BM, van der Graaf PH. Agoram BM, et al. Bioanalysis. 2012 Jun;4(10):1143-5. doi: 10.4155/bio.12.88. Bioanalysis. 2012. PMID: 22651555 No abstract available.
Physiologically based pharmacokinetics (PBPK).
Espié P, Tytgat D, Sargentini-Maier ML, Poggesi I, Watelet JB. Espié P, et al. Drug Metab Rev. 2009;41(3):391-407. doi: 10.1080/10837450902891360. Drug Metab Rev. 2009. PMID: 19601719 Review.
Pharmacokinetic and pharmacodynamic modeling in vivo.
Holford NH, Sheiner LB. Holford NH, et al. Crit Rev Bioeng. 1981;5(4):273-322. Crit Rev Bioeng. 1981. PMID: 7023829 Review.
What happened to the modeling and simulation revolution?
Bonate PL. Bonate PL. Clin Pharmacol Ther. 2014 Oct;96(4):416-7. doi: 10.1038/clpt.2014.123. Clin Pharmacol Ther. 2014. PMID: 25236664 No abstract available.

See all similar articles

Cited by

Evaluation of gender differences in the pharmacokinetics of oral zileuton nanocrystalline formulation using a rat model.
Muthumula CMR, Khare S, Jog R, Wickramaratne B, Lee A, Chakder S, Burgess DJ, Gokulan K. Muthumula CMR, et al. Int J Pharm X. 2024 May 4;7:100254. doi: 10.1016/j.ijpx.2024.100254. eCollection 2024 Jun. Int J Pharm X. 2024. PMID: 38774112 Free PMC article.
Review of Metabolomics-Based Biomarker Research for Parkinson's Disease.
Li X, Fan X, Yang H, Liu Y. Li X, et al. Mol Neurobiol. 2022 Feb;59(2):1041-1057. doi: 10.1007/s12035-021-02657-7. Epub 2021 Nov 26. Mol Neurobiol. 2022. PMID: 34826053 Review.
Model-Informed Dose Selection for a Novel Human Immunoglobulin G4 Derived Monoclonal Antibody Targeting Proprotein Convertase Kwashiorkor Type 9: Insights from Population Pharmacokinetics-Pharmacodynamics and Systems Pharmacology.
Peng J, Huang J, Tan H, Kuang Y, Yang G, Huang Z. Peng J, et al. ACS Pharmacol Transl Sci. 2024 Jan 17;7(2):406-420. doi: 10.1021/acsptsci.3c00256. eCollection 2024 Feb 9. ACS Pharmacol Transl Sci. 2024. PMID: 38357287 Free PMC article.
Current and future therapeutical approaches for COVID-19.
Duan Y, Yao Y, Kumar SA, Zhu HL, Chang J. Duan Y, et al. Drug Discov Today. 2020 Aug;25(8):1545-1552. doi: 10.1016/j.drudis.2020.06.018. Epub 2020 Jun 20. Drug Discov Today. 2020. PMID: 32574697 Free PMC article. Review.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information